Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$6.42 -4.6%	$4.51	$3.39 ▼ $16.00	$72.87M	0.77	69,778 shs	62,905 shs
DRUG Bright Minds Biosciences	$26.42 +1.1%	$27.68	$0.94 ▼ $79.02	$184.13M	-6.01	824,002 shs	17,170 shs
KOD Kodiak Sciences	$5.58 +9.8%	$3.93	$1.92 ▼ $11.60	$268.04M	2.28	352,441 shs	388,503 shs
PRME Prime Medicine	$4.53 -0.9%	$2.24	$1.11 ▼ $5.95	$609.27M	2.33	1.84 million shs	3.54 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-4.61%	+33.75%	+38.36%	+29.70%	-48.97%
DRUG Bright Minds Biosciences	+1.07%	+8.46%	-3.26%	-22.52%	+2,392.45%
KOD Kodiak Sciences	+9.84%	+16.01%	+54.14%	+39.85%	+86.62%
PRME Prime Medicine	-0.88%	+5.59%	+118.84%	+154.49%	-16.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	2.7678 of 5 stars	3.5	3.0	0.0	1.1	1.7	1.3
DRUG Bright Minds Biosciences	2.4521 of 5 stars	3.6	2.0	0.0	2.6	2.5	0.0
KOD Kodiak Sciences	3.6322 of 5 stars	3.0	2.0	4.6	0.6	3.3	0.0
PRME Prime Medicine	3.8696 of 5 stars	4.4	1.0	0.0	3.1	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	367.29% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	215.10% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	61.29% Upside
PRME Prime Medicine	2.75	Moderate Buy	$9.25	104.19% Upside

Current Analyst Ratings Breakdown

Latest AVTX, DRUG, KOD, and PRME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	158.02	N/A	N/A	$12.80 per share	0.50
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
PRME Prime Medicine	$3.85M	158.42	N/A	N/A	$1.37 per share	3.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest AVTX, DRUG, KOD, and PRME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	31.92%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	22.61	22.61
DRUG Bright Minds Biosciences	N/A	126.01	126.01
KOD Kodiak Sciences	N/A	4.62	4.62
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
DRUG Bright Minds Biosciences	40.52%
KOD Kodiak Sciences	89.06%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
DRUG Bright Minds Biosciences	42.66%
KOD Kodiak Sciences	45.90%
PRME Prime Medicine	22.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.80 million	Not Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
PRME Prime Medicine	234	134.50 million	100.38 million	Optionable

AVTX, DRUG, KOD, and PRME Headlines

Recent News About These Companies

Prime Medicine (NYSE:PRME) Shares Up 23.3% - Here's Why

July 21 at 3:13 PM | marketbeat.com

What is Wedbush's Estimate for Prime Medicine Q2 Earnings?

July 20 at 2:07 AM | americanbankingnews.com

Prime Medicine (NYSE:PRME) Stock Price Down 6.6% - Time to Sell?

July 18, 2025 | marketbeat.com

Wedbush Has Positive Forecast for Prime Medicine Q2 Earnings

July 18, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Receives Outperform Rating from Wedbush

July 18, 2025 | americanbankingnews.com

Prime Medicine's (PRME) "Outperform" Rating Reiterated at Wedbush

July 17, 2025 | marketbeat.com

Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements

July 17, 2025 | tipranks.com

Prime Medicine Shares Drop After New Funding, Equity Investment

July 16, 2025 | marketwatch.com

Prime Medicine (NYSE:PRME) Sees Large Volume Increase - Here's Why

July 16, 2025 | marketbeat.com

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

July 16, 2025 | businesswire.com

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

July 16, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading 7.4% Higher - Should You Buy?

July 14, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Shares Down 11.8% - Should You Sell?

July 11, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Sees Strong Trading Volume - What's Next?

July 9, 2025 | marketbeat.com

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

July 7, 2025 | seekingalpha.com

Prime Medicine stock soars amid gene editing sector momentum

July 7, 2025 | finance.yahoo.com

Prime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market Momentum

July 7, 2025 | tipranks.com

Stock Traders Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)

July 7, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Shares Gap Up - What's Next?

July 7, 2025 | marketbeat.com

Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data

July 6, 2025 | msn.com

Sumitomo Mitsui Trust Group Inc. Sells 164,157 Shares of Prime Medicine, Inc. (NYSE:PRME)

July 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

AVTX, DRUG, KOD, and PRME Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$6.42 -0.31 (-4.61%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$6.75 +0.33 (+5.14%)

As of 07/22/2025 07:57 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Bright Minds Biosciences NASDAQ:DRUG

$26.42 +0.28 (+1.07%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$24.28 -2.14 (-8.08%)

As of 07/22/2025 06:47 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Kodiak Sciences NASDAQ:KOD

$5.58 +0.50 (+9.84%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$5.56 -0.02 (-0.43%)

As of 07/22/2025 07:42 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Prime Medicine NYSE:PRME

$4.53 -0.04 (-0.88%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$4.53 +0.00 (+0.02%)

As of 07/22/2025 07:52 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time